Drug Search Results
More Filters [+]

Taldefgrobep alfa

Alternative Names: Taldefgrobep alfa, tadefgrobep alfa, rg-6206, rg 6206, rg6206, bms-986089, bms986089, bms 986089, ro-7239361, ro 7239361, ro7239361, BHV-2000, BHV2000, BHV 2000
Latest Update: 2024-11-19
Latest Update Note: Clinical Trial Update

Product Description

For Duchenne Muscular Dystrophy; (Sourced from: https://www.chugai-pharm.co.jp/english/profile/media/conference/files/181024ePresentation.pdf)

Mechanisms of Action: GDF8 Inhibitor

Novel Mechanism: Yes

Modality: Peptide/Protein

Route of Administration: Subcutaneous

FDA Designation:
Fast Track - Muscular Atrophy, Spinal|Muscular Atrophy
Orphan Drug - Muscular Atrophy, Spinal|Muscular Atrophy *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: Bristol-Myers Squibb

Clinical Description

Map of Global Clinical Trials for Taldefgrobep alfa

Countries in Clinic: Belgium, Czech Republic, Germany, Italy, Netherlands, Poland, Spain, United Kingdom, United States

Active Clinical Trial Count: 3

Highest Development Phases

Phase 3: Muscular Atrophy, Spinal|Spinal Diseases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

RESILIENT

P3

Active, not recruiting

Muscular Atrophy, Spinal

2025-11-02

BHV2000-301

P3

Unknown Status

Muscular Atrophy, Spinal

2025-10-08

RESILIENT

P3

Active, not recruiting

Muscular Atrophy, Spinal|Spinal Diseases

2025-01-01

95%

Recent News Events